• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

内脂素对非酒精性脂肪性肝病组织病理学变化的影响。

Influence of visfatin on histopathological changes of non-alcoholic fatty liver disease.

作者信息

Aller R, de Luis D A, Izaola O, Sagrado M Gonzalez, Conde R, Velasco M C, Alvarez T, Pacheco D, González J M

机构信息

Institute of Endocrinology and Nutrition, Medicine School and Unit of Investigation, Hospital Rio Hortega, University of Valladolid, C/Los perales 16, 47130, Simancas, Valladolid, Spain.

出版信息

Dig Dis Sci. 2009 Aug;54(8):1772-7. doi: 10.1007/s10620-008-0539-9. Epub 2008 Nov 14.

DOI:10.1007/s10620-008-0539-9
PMID:19005759
Abstract

BACKGROUND

Non-alcoholic fatty liver disease (NAFLD) is a common liver disease. The aim of the present study was to explore the relation of visfatin with underlying histopathological changes of NAFLD patients.

SUBJECTS

A population of 55 NAFLD patients was analyzed in a cross-sectional study. A liver biopsy was realized. Weight, basal glucose, insulin, insulin resistance (HOMA), total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, and visfatin levels were measured. A bioimpedance was performed.

RESULTS AND CONCLUSIONS

The mean age was 42.8 +/- 11.2 years, the mean BMI was 33.1 +/- 10.2 with 37 males (67.3%) and 18 females (32.7%). Probabilities to have; portal inflammation increased 1.11 (CI95%:1.03-1.50) with each increment of 1 ng/ml of visfatin concentration, high grade of steatosis increased 1.25 (CI 95%:1.06-1.61) with each unit of insulin concentrations, fibrosis increased 1.12 (CI 95%:1.02-1.43) with each unit of fat mass and lobulillar inflammation increased 13.4 (CI 95%:1.3-147) with each unit of HOMA-IR. Portal inflammation frequencies were different between groups (low visfatin group 13.07 < ng/ml: 37.5% versus high visfatin group 13.07 > ng/ml: 62.5%; P < 0.05). In conclusion, several histopathological changes in liver biopsies could be explained by insulin concentrations, HOMA-IR, and fat mass amount. Moreover, visfatin plasma concentrations could predict the presence of portal inflammation in NAFLD patients.

摘要

背景

非酒精性脂肪性肝病(NAFLD)是一种常见的肝脏疾病。本研究的目的是探讨内脂素与NAFLD患者潜在组织病理学变化之间的关系。

研究对象

在一项横断面研究中分析了55例NAFLD患者。进行了肝活检。测量了体重、基础血糖、胰岛素、胰岛素抵抗(HOMA)、总胆固醇、低密度脂蛋白胆固醇、高密度脂蛋白胆固醇、甘油三酯和内脂素水平。进行了生物电阻抗分析。

结果与结论

平均年龄为42.8±11.2岁,平均BMI为33.1±10.2,其中男性37例(67.3%),女性18例(32.7%)。内脂素浓度每增加1 ng/ml,门静脉炎症的发生概率增加1.11(95%置信区间:1.03 - 1.50);胰岛素浓度每增加一个单位,重度脂肪变性的发生概率增加1.25(95%置信区间:1.06 - 1.61);脂肪量每增加一个单位,纤维化的发生概率增加1.12(95%置信区间:1.02 - 1.43);HOMA-IR每增加一个单位,小叶炎症的发生概率增加13.4(95%置信区间:1.3 - 147)。不同组之间门静脉炎症频率不同(内脂素水平低组<13.07 ng/ml:37.5%,内脂素水平高组>13.07 ng/ml:62.5%;P<0.05)。总之,肝活检中的几种组织病理学变化可以用胰岛素浓度、HOMA-IR和脂肪量来解释。此外,血浆内脂素浓度可以预测NAFLD患者门静脉炎症的存在。

相似文献

1
Influence of visfatin on histopathological changes of non-alcoholic fatty liver disease.内脂素对非酒精性脂肪性肝病组织病理学变化的影响。
Dig Dis Sci. 2009 Aug;54(8):1772-7. doi: 10.1007/s10620-008-0539-9. Epub 2008 Nov 14.
2
The relationship between circulating visfatin/nicotinamide phosphoribosyltransferase, obesity, inflammation and lipids profile in elderly population, determined by structural equation modeling.通过结构方程模型确定老年人群中循环内脂素/烟酰胺磷酸核糖转移酶、肥胖、炎症与血脂谱之间的关系。
Scand J Clin Lab Invest. 2016 Dec;76(8):632-640. doi: 10.1080/00365513.2016.1230884. Epub 2016 Oct 7.
3
Association of plasma visfatin with hepatic and systemic inflammation in nonalcoholic fatty liver disease.血浆内脂素与非酒精性脂肪性肝病的肝及全身炎症的相关性。
Ann Hepatol. 2013 Jul-Aug;12(4):548-55.
4
Visfatin is associated with lipid metabolic abnormalities in Lyon hypertensive rats.内脂素与里昂高血压大鼠的脂代谢异常有关。
Clin Exp Pharmacol Physiol. 2010 Sep;37(9):894-9. doi: 10.1111/j.1440-1681.2010.05402.x. Epub 2010 Apr 26.
5
Lys656Asn polymorphism of leptin receptor, leptin levels and insulin resistance in patients with non alcoholic fatty liver disease.瘦素受体 Lys656Asn 多态性、瘦素水平与非酒精性脂肪性肝病患者胰岛素抵抗的关系。
Eur Rev Med Pharmacol Sci. 2012 Mar;16(3):335-41.
6
Influence of insulin resistance and adipokines in the grade of steatosis of nonalcoholic fatty liver disease.胰岛素抵抗和脂肪因子对非酒精性脂肪性肝病脂肪变性程度的影响。
Dig Dis Sci. 2008 Apr;53(4):1088-92. doi: 10.1007/s10620-007-9981-3. Epub 2007 Oct 13.
7
Visceral adipose tissue visfatin in nonalcoholic fatty liver disease.非酒精性脂肪性肝病中的内脏脂肪组织内脏素。
Ann Hepatol. 2010 Jul-Sep;9(3):266-70.
8
Adipocytokines and cytokeratin-18 in patients with nonalcoholic fatty liver disease: Introduction of CHA index.非酒精性脂肪性肝病患者的脂肪细胞因子和细胞角蛋白-18:CHA 指数的引入。
Ann Hepatol. 2013 Sep-Oct;12(5):749-57.
9
Relation of osteocalcin with insulin resistance and histopathological changes of non alcoholic fatty liver disease.骨钙素与胰岛素抵抗及非酒精性脂肪性肝病组织病理学变化的关系。
Ann Hepatol. 2011 Jan-Mar;10(1):50-5.
10
Plasma visfatin levels in severe obstructive sleep apnea-hypopnea syndrome.严重阻塞性睡眠呼吸暂停低通气综合征患者的血浆内脂素水平。
Sleep Breath. 2009 Nov;13(4):349-55. doi: 10.1007/s11325-009-0254-6. Epub 2009 Apr 10.

引用本文的文献

1
Biochemical study of the effect of lead exposure in nonobese gasoline station workers and risk of hyperglycemia: A retrospective case-control study.非肥胖型加油站工人接触铅暴露的生化研究及其与高血糖风险的关系:一项回顾性病例对照研究。
Medicine (Baltimore). 2024 Aug 9;103(32):e39152. doi: 10.1097/MD.0000000000039152.
2
Advances in Noninvasive Biomarkers for Nonalcoholic Fatty Liver Disease.非酒精性脂肪性肝病无创生物标志物的进展
Metabolites. 2023 Oct 29;13(11):1115. doi: 10.3390/metabo13111115.
3
The Predictive Role of Extracellular NAPRT for the Detection of Advanced Fibrosis in Biopsy-Proven Non-Alcoholic Fatty Liver Disease.

本文引用的文献

1
Correlation of circulating full-length visfatin (PBEF/NAMPT) with metabolic parameters in subjects with and without diabetes: a cross-sectional study.糖尿病患者与非糖尿病患者循环中全长内脂素(PBEF/NAMPT)与代谢参数的相关性:一项横断面研究
Clin Endocrinol (Oxf). 2008 Dec;69(6):885-93. doi: 10.1111/j.1365-2265.2008.03264.x. Epub 2008 Apr 10.
2
Effect of a hypocaloric diet on serum visfatin in obese non-diabetic patients.低热量饮食对肥胖非糖尿病患者血清内脂素的影响。
Nutrition. 2008 Jun;24(6):517-21. doi: 10.1016/j.nut.2008.01.052. Epub 2008 Mar 17.
3
Visfatin: a putative biomarker for metabolic syndrome is not influenced by pioglitazone or simvastatin treatment in nondiabetic patients at cardiovascular risk -- results from the PIOSTAT study.
细胞外 NAPRT 对活检证实的非酒精性脂肪性肝病中晚期纤维化检测的预测作用。
Int J Mol Sci. 2023 Jan 7;24(2):1172. doi: 10.3390/ijms24021172.
4
Adipokines in Non-Alcoholic Fatty Liver Disease: Are We on the Road toward New Biomarkers and Therapeutic Targets?非酒精性脂肪性肝病中的脂肪因子:我们正朝着新的生物标志物和治疗靶点迈进吗?
Biology (Basel). 2022 Aug 19;11(8):1237. doi: 10.3390/biology11081237.
5
Non-Alcoholic Fatty Liver Disease in HIV/HBV Patients - a Metabolic Imbalance Aggravated by Antiretroviral Therapy and Perpetuated by the Hepatokine/Adipokine Axis Breakdown.HIV/HBV 患者的非酒精性脂肪性肝病——由抗逆转录病毒疗法加重的代谢失衡,并被肝肠肽/脂肪因子轴的破坏所延续。
Front Endocrinol (Lausanne). 2022 Mar 9;13:814209. doi: 10.3389/fendo.2022.814209. eCollection 2022.
6
Serum Visfatin Levels in Nonalcoholic Fatty Liver Disease and Liver Fibrosis: Systematic Review and Meta-Analysis.非酒精性脂肪性肝病和肝纤维化患者的血清内脂素水平:系统评价与Meta分析
J Clin Med. 2021 Jul 7;10(14):3029. doi: 10.3390/jcm10143029.
7
Assessment of the association between body composition and risk of non-alcoholic fatty liver.评估身体成分与非酒精性脂肪肝风险之间的关联。
PLoS One. 2021 Apr 1;16(4):e0249223. doi: 10.1371/journal.pone.0249223. eCollection 2021.
8
Nicotinamide and NAFLD: Is There Nothing New Under the Sun?烟酰胺与非酒精性脂肪性肝病:难道太阳底下无新事?
Metabolites. 2019 Sep 10;9(9):180. doi: 10.3390/metabo9090180.
9
Visfatin Induces Inflammation and Insulin Resistance via the NF-B and STAT3 Signaling Pathways in Hepatocytes.内脂素通过 NF-B 和 STAT3 信号通路在肝细胞中诱导炎症和胰岛素抵抗。
J Diabetes Res. 2019 Jul 17;2019:4021623. doi: 10.1155/2019/4021623. eCollection 2019.
10
Identification of Novel Regulatory Genes in APAP Induced Hepatocyte Toxicity by a Genome-Wide CRISPR-Cas9 Screen.通过全基因组 CRISPR-Cas9 筛选鉴定 APAP 诱导的肝细胞毒性的新调控基因。
Sci Rep. 2019 Feb 4;9(1):1396. doi: 10.1038/s41598-018-37940-6.
内脂素:一种代谢综合征的假定生物标志物不受吡格列酮或辛伐他汀治疗的影响,该研究为心血管疾病风险的非糖尿病患者的PIOSTAT研究结果。
Horm Metab Res. 2007 Oct;39(10):764-8. doi: 10.1055/s-2007-985867.
4
Pathologic assessment of non-alcoholic fatty liver disease.非酒精性脂肪性肝病的病理评估
Clin Liver Dis. 2007 Feb;11(1):17-23, vii. doi: 10.1016/j.cld.2007.02.002.
5
Standards of medical care in diabetes--2007.《2007年糖尿病医疗护理标准》
Diabetes Care. 2007 Jan;30 Suppl 1:S4-S41. doi: 10.2337/dc07-S004.
6
Changes and relations of circulating visfatin, apelin, and resistin levels in normal, impaired glucose tolerance, and type 2 diabetic subjects.正常、糖耐量受损及2型糖尿病患者循环中内脂素、脂联素和抵抗素水平的变化及关系
Exp Clin Endocrinol Diabetes. 2006 Nov;114(10):544-8. doi: 10.1055/s-2006-948309.
7
Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerance.新诊断且未经治疗的2型糖尿病和糖耐量受损患者的血浆内脂素水平
Diabetes Res Clin Pract. 2007 Apr;76(1):24-9. doi: 10.1016/j.diabres.2006.07.031. Epub 2006 Sep 7.
8
Interleukin-6 is a key mediator of the hepatoprotective and pro-proliferative effects of ischaemic preconditioning in mice.白细胞介素-6是小鼠缺血预处理的肝脏保护和促增殖作用的关键介质。
J Hepatol. 2006 Jul;45(1):20-7. doi: 10.1016/j.jhep.2006.01.039. Epub 2006 Mar 20.
9
IL-6-deficient mice are susceptible to ethanol-induced hepatic steatosis: IL-6 protects against ethanol-induced oxidative stress and mitochondrial permeability transition in the liver.白细胞介素-6缺陷型小鼠易患乙醇诱导的肝脂肪变性:白细胞介素-6可保护肝脏免受乙醇诱导的氧化应激和线粒体通透性转换的影响。
Cell Mol Immunol. 2004 Jun;1(3):205-11.
10
Plasma visfatin concentrations and fat depot-specific mRNA expression in humans.人体血浆内脂素浓度及脂肪储存部位特异性mRNA表达
Diabetes. 2005 Oct;54(10):2911-6. doi: 10.2337/diabetes.54.10.2911.